Draft guidance to inform industries developing nanoengineered products about the approach the Food and Drug Administration will take in regulating those goods was published June 14 in the Federal Register (76 Fed. Reg. 34,715).
FDA is seeking comment on the guidance, which “is intended to help industry and others identify when they should consider potential implications for regulatory status, effectiveness, or public heath impact that may arise with the application of nanotechnology in FDA-registered products.”
The guidance applies to all FDA-regulated products, including items such as food-contact materials, cosmetics, and sunscreens that can be made with nanotechnologies, an FDA spokesman confirmed June 10.
The guidance is part of a package of proposed or final policies toward nanoengineered products that federal agencies released in conjunction with a White House memo providing overarching principles for regulating nanomaterials (35 CRR 582, 6/13/11).
The guidance does not provide a regulatory definition of nanotechnology.
Instead, the draft document describes factors the agency will consider to determine whether a product may be designed with nanotechnology.
These factors include whether an engineered material or product has at least one dimension in the nanoscale, which is described as ranging from 1 nanometer to 100 nanometers, and whether the material exhibits specific properties that could affect its function or toxicity.
Such novel properties could be important even if the material is up to 1,000 nanometers in size, FDA said.
Factors FDA would consider include whether the size or special properties enhance the protection offered by food packaging materials or better detect pathogens.
“For products subject to premarket review, the FDA intends to apply the points in the draft guidance, when finalized, to better understand the properties and behavior of engineered nanomaterials,” the agency said in an announcement of the document.
“For products not subject to premarket review, the FDA will urge manufacturers to consult with the agency early in the product development process so questions related to the regulatory status, safety, effectiveness, or public health impact of these products can be adequately addressed,” it said.
Comments on FDA's draft guidance is due by Aug. 15. Comments should be marked docket number FDA-2010-D-0530 and submitted at http://www.regulations.gov.
By Pat Rizzuto
The draft guidance is available at http://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm .
FDA also published questions and answers concerning its draft guidance. They are available at http://www.fda.gov/ScienceResearch/SpecialTopics/Nanotechnology/ucm258391.htm .
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)